Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy
It is known that the interleukin-4 receptor α (IL-4Rα) is highly expressed on the surface of various human solid tumors. We previously designed novel IL-4Rα-lytic hybrid peptide composed of binding peptide to IL-4Rα and cell-lytic peptide and reported that the designed IL-4Rα-lytic hybrid peptide ex...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | International Journal of Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2014/584650 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568056398741504 |
|---|---|
| author | Kahori Seto Junichi Shoda Tomohisa Horibe Eiji Warabi Masayuki Kohno Toru Yanagawa Hiroki Bukawa Yasuni Nakanuma Koji Kawakami |
| author_facet | Kahori Seto Junichi Shoda Tomohisa Horibe Eiji Warabi Masayuki Kohno Toru Yanagawa Hiroki Bukawa Yasuni Nakanuma Koji Kawakami |
| author_sort | Kahori Seto |
| collection | DOAJ |
| description | It is known that the interleukin-4 receptor α (IL-4Rα) is highly expressed on the surface of various human solid tumors. We previously designed novel IL-4Rα-lytic hybrid peptide composed of binding peptide to IL-4Rα and cell-lytic peptide and reported that the designed IL-4Rα-lytic hybrid peptide exhibited cytotoxic and antitumor activity both in vitro and in vivo against the human pancreatic cancer cells expressing IL-4Rα. Here, we evaluated the antitumor activity of the IL-4Rα-lytic hybrid peptide as a novel molecular targeted therapy for human biliary tract cancer (BTC). The IL-4Rα-lytic hybrid peptide showed cytotoxic activity in six BTC cell lines with a concentration that killed 50% of all cells (IC50) as low as 5 μM. We also showed that IL-4Rα-lytic hybrid peptide in combination with gemcitabine exhibited synergistic cytotoxic activity in vitro. In addition, intravenous administration of IL-4Rα-lytic hybrid peptide significantly inhibited tumor growth in a xenograft model of human BTC in vivo. Taken together, these results indicated that the IL-4Rα-lytic hybrid peptide is a potent agent that might provide a novel therapy for patients with BTC. |
| format | Article |
| id | doaj-art-19f26fedd35b4540bf33fbdb8f966b8d |
| institution | Kabale University |
| issn | 2090-3448 2090-3456 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hepatology |
| spelling | doaj-art-19f26fedd35b4540bf33fbdb8f966b8d2025-02-03T00:59:49ZengWileyInternational Journal of Hepatology2090-34482090-34562014-01-01201410.1155/2014/584650584650Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer TherapyKahori Seto0Junichi Shoda1Tomohisa Horibe2Eiji Warabi3Masayuki Kohno4Toru Yanagawa5Hiroki Bukawa6Yasuni Nakanuma7Koji Kawakami8Department of Oral and Maxillofacial Surgery, Clinical Sciences, University of Tsukuba, Ibaraki 305-8575, JapanMedical Science, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, JapanDepartment of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, JapanDivision of Biomedical Science, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, JapanDepartment of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, JapanDepartment of Oral and Maxillofacial Surgery, Clinical Sciences, University of Tsukuba, Ibaraki 305-8575, JapanDepartment of Oral and Maxillofacial Surgery, Clinical Sciences, University of Tsukuba, Ibaraki 305-8575, JapanDepartment of Human Pathology, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-1192, JapanDepartment of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, JapanIt is known that the interleukin-4 receptor α (IL-4Rα) is highly expressed on the surface of various human solid tumors. We previously designed novel IL-4Rα-lytic hybrid peptide composed of binding peptide to IL-4Rα and cell-lytic peptide and reported that the designed IL-4Rα-lytic hybrid peptide exhibited cytotoxic and antitumor activity both in vitro and in vivo against the human pancreatic cancer cells expressing IL-4Rα. Here, we evaluated the antitumor activity of the IL-4Rα-lytic hybrid peptide as a novel molecular targeted therapy for human biliary tract cancer (BTC). The IL-4Rα-lytic hybrid peptide showed cytotoxic activity in six BTC cell lines with a concentration that killed 50% of all cells (IC50) as low as 5 μM. We also showed that IL-4Rα-lytic hybrid peptide in combination with gemcitabine exhibited synergistic cytotoxic activity in vitro. In addition, intravenous administration of IL-4Rα-lytic hybrid peptide significantly inhibited tumor growth in a xenograft model of human BTC in vivo. Taken together, these results indicated that the IL-4Rα-lytic hybrid peptide is a potent agent that might provide a novel therapy for patients with BTC.http://dx.doi.org/10.1155/2014/584650 |
| spellingShingle | Kahori Seto Junichi Shoda Tomohisa Horibe Eiji Warabi Masayuki Kohno Toru Yanagawa Hiroki Bukawa Yasuni Nakanuma Koji Kawakami Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy International Journal of Hepatology |
| title | Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy |
| title_full | Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy |
| title_fullStr | Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy |
| title_full_unstemmed | Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy |
| title_short | Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy |
| title_sort | targeting interleukin 4 receptor alpha by hybrid peptide for novel biliary tract cancer therapy |
| url | http://dx.doi.org/10.1155/2014/584650 |
| work_keys_str_mv | AT kahoriseto targetinginterleukin4receptoralphabyhybridpeptidefornovelbiliarytractcancertherapy AT junichishoda targetinginterleukin4receptoralphabyhybridpeptidefornovelbiliarytractcancertherapy AT tomohisahoribe targetinginterleukin4receptoralphabyhybridpeptidefornovelbiliarytractcancertherapy AT eijiwarabi targetinginterleukin4receptoralphabyhybridpeptidefornovelbiliarytractcancertherapy AT masayukikohno targetinginterleukin4receptoralphabyhybridpeptidefornovelbiliarytractcancertherapy AT toruyanagawa targetinginterleukin4receptoralphabyhybridpeptidefornovelbiliarytractcancertherapy AT hirokibukawa targetinginterleukin4receptoralphabyhybridpeptidefornovelbiliarytractcancertherapy AT yasuninakanuma targetinginterleukin4receptoralphabyhybridpeptidefornovelbiliarytractcancertherapy AT kojikawakami targetinginterleukin4receptoralphabyhybridpeptidefornovelbiliarytractcancertherapy |